NextCure Inc

$9.42 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About NextCure Inc

Nextcure Inc. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases. The Company uses its functional integrated nextcure discovery in immune oncology (FIND-IO) technology to functional screening approaches for the identification of targets from multiple therapeutic areas, including autoimmunity and neurology, enabling immunomedicine to treat unmet medical needs. Its product pipelines include NC318, a immunotherapeutic against a immunomodulatory target found on a restricted set of myeloid and tumor cells, and NC410, a immunomedicine designed to block an immune regulator expressed on T cells and suppressive antigen-presenting cell populations, including dendritic cell subpopulations.

Stock Analysis

last close $9.42
1-mo return -24%
3-mo return -23.5%
avg daily vol. 168.64T
52-week high 39.77
52-week low 7.91
market cap. $266M
forward pe -
annual div. -
roe -11.9%
ltg forecast -
dividend yield -
annual rev. $22M
inst own. 71.4%

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist